The U.S. Drug Enforcement Administration (DEA) has proposed a major increase in quotas that govern the production and supply of psilocybin for research purposes. The proposed adjustments—which would represent a 50x increase in the quota for psilocybin, for example—would likely reduce friction around the acquisition of such substances for both nonclinical and clinical research. Elsewhere…


Previous articlePTSF75 – Possession Limits, Religion, and Scalability
Next articlePT261 – Dr. Tiago Reis Marques – Ketamine, New Drugs, and the Repurposing of Current Drugs